The inclusion criteria for this study were defined as follows: TPS PD-L1 score of >30% or <10%; complete molecular profiling according to the 2021 CNS WHO classification; methylome profiling with the molecular glioblastoma subtypes mesenchymal, RTK I, RTK II, and midline. This evidence concerns the gene CD274 and glioblastoma.